抗PD-1治疗后HIV储存库衰减与固有抗病毒及免疫功能相关
在1期CITN-12试验中,对30例合并癌症的HIV感染者(29男1女)接受帕博利珠单抗治疗进行预设的探索性纵向多组学分析;治疗总体耐受良好,5例出现客观抗肿瘤反应。治疗24小时内增殖性HIV特异性效应CD8+ T细胞扩增、血浆TGFβ下降;14例追踪至治疗结束者中9例显示干扰素刺激基因等早期诱导并持续表达且HIV储存库减少。
要点
- 帕博利珠单抗在合并癌症的HIV感染者中总体耐受良好,多数不良事件为1-2级。
- 治疗24小时内可见增殖性HIV特异性效应CD8+ T细胞扩增及血浆TGFβ下降。
- 14例追踪至治疗结束者中9例出现ISGs、抗病毒限制因子和TLR信号早期诱导并持续表达,同时HIV储存库减少。
核心结论
- 这些发现定义了有助于识别最可能从抗PD-1治疗中获得储存库衰减的HIV感染者的免疫通路,并提示持续的ISG激活可能有助于储存库减少及ART中断后预防病毒反弹。
研究设计与样本
- 预设的探索性纵向多组学分析,纳入1期CITN-12临床试验中30例合并癌症的HIV感染者(29男1女),评估帕博利珠单抗的安全性和初步抗肿瘤活性。
主要发现
- 治疗总体耐受良好,多数不良事件为1-2级,5例观察到客观抗肿瘤反应(1例完全缓解、4例部分缓解)。
- 治疗24小时内观察到增殖性HIV特异性效应CD8+ T细胞扩增和血浆TGFβ下降。
- 14例追踪至治疗结束者(治疗开始后44至315天)中,9例显示干扰素刺激基因、抗病毒限制因子和Toll样受体信号的早期诱导与持续表达,并伴有HIV储存库减少。
- 将上述转录组特征映射到1000余个公开单细胞RNA测序数据集,发现抗PD-1诱导的程序存在于多种疾病状态的亚群中,提示部分人已呈现增强的抗病毒状态。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antiretroviral therapy (ART) suppresses HIV but does not eliminate the latent viral reservoir, which persists in programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. Anti-PD-1 therapies have reduced the HIV reservoir in people living with HIV (PLWH) and cancer; however, the individuals who benefit and the mechanisms driving reservoir reduction remain unclear. We performed a prespecified exploratory, longitudinal multiomic profiling of 30 PLWH (29 males and one female) with cancer in the phase 1 CITN-12 clinical trial, in which pembrolizumab was evaluated for safety and preliminary antitumor activity. The therapy was generally well tolerated, with most adverse events graded 1-2 and objective antitumor response observed in five participants (one complete response and four partial responses). Within 24 hours of treatment, we observed an expansion of proliferating HIV-specific effector CD8+ T cells and a decline in plasma TGFβ. Furthermore, among the 14 participants tracked to the end of treatment (ranging from 44 to 315 days after therapy initiation), nine display early induction and sustained expression of interferon-stimulated genes (ISGs), antiviral restriction factors and Toll-like receptor (TLR) signaling and a reduction in the HIV reservoir. Mapping these transcriptomic signatures across more than 1,000 public single-cell RNA sequencing datasets reveals that anti-PD-1-induced programs are present in subsets of across subsets of disease states, indicating that some people already display a heightened antiviral state. Together, these findings define immune pathways that help identify PLWH most likely to experience reservoir decay with anti-PD-1 therapy and suggest that sustained ISG activation may contribute to reservoir reduction and prevention of viral rebound upon ART interruption. ClinicalTrials.gov registration: NCT02595866 .
引用
- Talla A, Azevedo JLLC, Latif MB, et al. Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy. Nat Med. 2026. PMID: 41680482. doi:10.1038/s41591-025-04139-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。